COST-EFFECTIVENESS OF VARENICLINE VERSUS EXISTING SMOKING CESSATION STRATEGIES IN BRAZIL FROM THE PUBLIC PERSPECTIVE, USING THE BENESCO MODEL

被引：0
|
作者：
Fujii, R. [1 ]
Correia, E. A. [1 ]
Mould, J. F. [2 ]
机构：
[1] Pfizer Pharmaceut Inc, Sao Paulo, Brazil
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1388
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A487 / A487
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF VARENICLINE VERSUS EXISTING SMOKING CESSATION STRATEGIES IN CENTRAL AMERICA AND THE CARIBBEAN USING THE BENESCO MODEL
    Lutz, M.
    Lovato, P.
    Cuesta, G.
    VALUE IN HEALTH, 2011, 14 (03) : A139 - A139
  • [2] COST-EFFECTIVENESS OF VARENICLINE VS EXISTING SMOKING CESSATION STRATEGIES IN DOMINICAN REPUBLIC USING THE BENESCO MODEL
    Lutz, M.
    Morales, G.
    Cuesta, G.
    VALUE IN HEALTH, 2011, 14 (07) : A566 - A566
  • [3] Cost-Effectiveness Analysis of Varenicline Versus Currently Funded Smoking Cessation Strategies in Brazil
    Alves Fernandes, Ricardo Ribeiro
    Seixas, Brayan Viegas
    Szklo, Andre Salem
    Guerra, Renata Leborato
    Barufaldi, Laura Augusta
    Ribeiro de Albuquerque, Rita de Cassia
    de Mello Vianna, Cid Manso
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 27 : 25 - 31
  • [4] A cost-effectiveness model for smoking cessation therapy using varenicline
    Viswanathan, S.
    Neville, W.
    Patel, E.
    Raparla, S.
    McGhan, W. F.
    VALUE IN HEALTH, 2008, 11 (03) : A270 - A271
  • [5] Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model - Application to a population of US adult smokers
    Howard, Paul
    Knight, Christopher
    Boler, Annabel
    Baker, Christine
    PHARMACOECONOMICS, 2008, 26 (06) : 497 - 511
  • [6] Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation ModelApplication to a Population of US Adult Smokers
    Paul Howard
    Christopher Knight
    Annabel Boler
    Christine Baker
    PharmacoEconomics, 2008, 26 : 497 - 511
  • [7] THE COST-EFFECTIVENESS OF VARENICLINE IN SMOKING CESSATION IN DENMARK
    Poulsen, P. B.
    Dollerup, J.
    Keiding, H.
    VALUE IN HEALTH, 2008, 11 (06) : A450 - A450
  • [8] COST EFFECTIVENESS OF VARENICLINE COMPARED WITH EXISTING SMOKING CESSATION STRATEGIES IN HONG KONG
    Lee, K. K.
    Lee, V. W. Y.
    Chow, D. P.
    VALUE IN HEALTH, 2009, 12 (07) : A301 - A301
  • [9] THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING CESSATION IN POLAND
    Walczak, J.
    Nogas, G.
    Dybek-Karpiuk, A.
    Augustynska, J.
    Stelmachowski, J.
    Garbacka, M.
    Obrzut, G.
    Pawlik, D.
    VALUE IN HEALTH, 2009, 12 (07) : A303 - A303
  • [10] COST-UTILITY ANALYSIS OF VARENICLINE VERSUS EXISTING SMOKING CESSATION STRATEGIES IN KOREA
    Park, D. J.
    Kim, Y. H.
    Kim, E. J.
    VALUE IN HEALTH, 2014, 17 (07) : A726 - A726
12345